CLDX / Celldex Therapeutics, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 Celldex Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commiss

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Exhibit 99.1 Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) · Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tract · Profound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a primary driver in EoE · Favorable saf

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Celldex Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commissi

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

EXHIBIT 99.1 Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of barzolvolimab dosing Data anticipated from Phase 2 studies of barzolvolimab in EoE an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Celldex Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commission

Filing Fee Table*

Calculation of Filing Fee Tables S-8 Celldex Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001 par value per share Other 2,000,000 $ 40,030,000.00 0.0001531 $ 6,128.59 Total Offeri

As filed with the Securities and Exchange Commission on June 6, 2025

As filed with the Securities and Exchange Commission on June 6, 2025 Registration No.

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

Exhibit 99.1 Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors HAMPTON, N.J., June 6, 2025 - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors. “We are excited to welcome Denice to the Celldex Board of Directors,” said Anthony Marucci, Co-founder, President and Chief Executive Officer

Amendment No. 3 to Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan

Exhibit 10.1 AMENDMENT No. 3 TO CELLDEX THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Dated: April 10, 2025 This Agreement amends the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”). All capitalized terms not defined herein shall have the meanings set forth in the Plan. R E C I T A L S WHEREAS, Section 17.2 of the Plan reserves to the Board of Directors (“Board”)

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

EXHIBIT 99.1 Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update Strong execution and progress across pipeline with multiple key data read outs expected in 2025 Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in June Phase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU under development Phase 2 EOE study enrollment compl

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

Subsidiaries of Celldex Therapeutics, Inc.

Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. Name Jurisdiction of Organization Ownership Percentage Celldex Therapeutics Switzerland GmbH Switzerland 100%

Celldex Therapeutics, Inc. Insider Trading Policy

Exhibit 19.1 INSIDER TRADING POLICY (Revised February 12, 2025 ) This Insider Trading Policy (this “Policy”) of Celldex Therapeutics, Inc. (the “Company” or “Celldex”) is designed to prevent insider trading or allegations of insider trading, protect the Company’s reputation for integrity and ethical conduct and to assist Insiders (as defined below) in complying with their obligations under the fed

Fourth Amendment to Lease Agreement between the Company and Perryville SPE LLC (successor-in-interest) to Crown Perryville, LLC dated as of October 30, 2024

Exhibit 10.17 FOURTH AMENDMENT TO LEASE AGREEMENT This Fourth Amendment to Lease Agreement (this “Amendment”) is made and entered into as of October 30, 2024 (“Effective Date”), by and between PERRYVILLE SPE, LLC, a limited liability company (“Landlord”), and CELLDEX THERAPEUTICS, INC. (“Tenant”). W I T N E S S E T H: WHEREAS, Landlord’s predecessor-in-interest, Crown Perryville, LLC., and Tenant

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-15006 CELLDEX THERAPEUTICS, INC. (Exa

Eleventh Amendment to Lease by and between the Company and University of Massachusetts Dartmouth dated as of December 1, 2024

Exhibit 10.12 ELEVENTH AMENDMENT TO LEASE This ELEVENTH AMENDMENT TO LEASE (this “Amendment”) is made as of the 1st day of December, 2024, (the “Effective Date”) by and between UNIVERSITY OF MASSACHUSETTS DARTMOUTH, an institution of Higher Education of the Commonwealth of Massachusetts, with an address of 285 Old Westport Rd. North Dartmouth Massachusetts 02747 (“Landlord”) and CELLDEX THERAPEUTI

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

EXHIBIT 99.1 Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under development Phase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollment ongoing in Phase 2 PN study Celldex’s first bispecific for inflammatory diseases, CDX-

CLDX / Celldex Therapeutics, Inc. / RTW INVESTMENTS, LP - CELLDEX THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p24-3192sc13ga.htm CELLDEX THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this stat

CLDX / Celldex Therapeutics, Inc. / Point72 Asset Management, L.P. Passive Investment

SC 13G/A 1 p24-3151sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat

CLDX / Celldex Therapeutics, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment

SC 13G/A 1 eventidecelldex-sc13g.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Celldex Therapeutics, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.001 (Title of Class of Securities) 15117B202 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of th

CLDX / Celldex Therapeutics, Inc. / Polar Capital Holdings Plc Passive Investment

SC 13G/A 1 polar-cldx093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* CELLDEX THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $.001 (Title of Class of Securities) 15117B202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro

JOINT FILING AGREEMENT

EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Celldex Therapeutics, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-

CLDX / Celldex Therapeutics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15117B202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exac

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

EXHIBIT 99.1 Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update Enrollment continues in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under development All primary and secondary endpoints met with high statistical significance in global Phase 2 CIndU study Long term 52 week treatment data in landmark, global Phase 2 CSU study demonstrated deepening of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact nam

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commissi

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

EXHIBIT 99.1 Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update Phase 3 CSU studies initiated July 2024 Positive topline Phase 2 CIndU 12 week data reported July 2024 supporting Phase 3 advancement 52 week Phase 2 CSU data and full 12 week Phase 2 CIndU data to be reported 2H 2024 Enrollment continues in Phase 2 PN and EOE studies; Phase 2 AD study to start YE 2024

Amendment No. 2 to Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan

Exhibit 10.1 AMENDMENT No. 2 TO CELLDEX THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Dated: April 12, 2024 This Amendment amends the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”). All capitalized terms not defined herein shall have the meanings set forth in the Plan. R E C I T A L S WHEREAS, Section 17.2 of the Plan reserves to the Board of Directors (“Board”)

As filed with the Securities and Exchange Commission on June 14, 2024

As filed with the Securities and Exchange Commission on June 14, 2024 Registration No.

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Celldex Therapeutics, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update - Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data

EXHIBIT 99.1 Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update - Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment completed in Phase 2 CIndU study; 12 week data expected 2H 2024 - - Phase 2 PN study initiated;

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact na

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

8,520,000 Shares COMMON STOCK

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-275300 PROSPECTUS SUPPLEMENT (To Prospectus dated November 3, 2023) 8,520,000 Shares COMMON STOCK We are offering 8,520,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “CLDX.” The last reported sale price of our common stock on February 29,

Calculation of Filing Fee Tables (Form Type) Celldex Therapeutics, Inc. (Exact Name of Each Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Exhibit 99.1 Celldex Therapeutics Announces Proposed Public Offering of Common Stock HAMPTON, N.J., February 28, 2024 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering. Celldex expects to grant

Underwriting Agreement, dated February 29, 2024, by and among Celldex Therapeutics, Inc. and Leerink Partners LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein

Exhibit 1.1 CELLDEX THERAPEUTICS, INC. 8,520,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement February 29, 2024 LEERINK PARTNERS LLC COWEN AND COMPANY, LLC As Representatives of the several Underwriters  c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10022 Ladies and G

Financial Statements and Exhibits, Other Events, Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commi

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Exhibit 99.2 Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock HAMPTON, N.J., February 29, 2024 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share. All of the

$250,000,000 COMMON STOCK

TABLE OF CONTENTS The information in this preliminary prospectus is not complete and may be changed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-15006 CELLDEX THERAPEUTICS, INC. (Exa

Up to $300,000,000 Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-275300 PROSPECTUS SUPPLEMENT (To Prospectus dated November 3, 2023) Up to $300,000,000 Common Stock In accordance with the terms of the Controlled Equity OfferingSM sales agreement, dated February 26, 2024, or the Sales Agreement, we entered into with Cantor Fitzgerald & Co., or Cantor, we may offer and sell shares of our co

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update - Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024

EXHIBIT 99.1 Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update - Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment nearing completion in Phase 2 CIndU study; Data expected 2H 2024 - - Phase 2 PN s

Sales Agreement, dated February 26, 2024, by and between Celldex Therapeutics, Inc. and Cantor Fitzgerald & Co.

Exhibit 1.1 CELLDEX THERAPEUTICS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement February 26, 2024 Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 Ladies and Gentlemen: Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as fol

Subsidiaries of Celldex Therapeutics, Inc.

Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. Name Jurisdiction of Organization Ownership Percentage Celldex Therapeutics Switzerland GmbH Switzerland 100%

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 Celldex Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commi

Celldex Therapeutics, Inc. Compensation Recovery Policy

Exhibit 97 CELLDEX THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY (Adopted and approved on September 14, 2023, and effective as of December 1, 2023) 1. Purpose Celldex Therapeutics, Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this comm

Calculation of Filing Fee Tables (Form Type) Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Celldex Therapeutics, Inc.

CLDX / Celldex Therapeutics, Inc. / Kynam Capital Management, LP - KYNAM CAPITAL MANAGEMENT, LP Passive Investment

SC 13G 1 cldx21424.htm KYNAM CAPITAL MANAGEMENT, LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the approp

CLDX / Celldex Therapeutics, Inc. / Point72 Asset Management, L.P. - CELLDEX THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p24-0668sc13ga.htm CELLDEX THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this State

CLDX / Celldex Therapeutics, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment

SC 13G 1 celldexthera-eventide13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Celldex Therapeutics, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2023 (Date of Event which Requires Fili

CLDX / Celldex Therapeutics, Inc. / RTW INVESTMENTS, LP - CELLDEX THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p24-0389sc13ga.htm CELLDEX THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this state

CLDX / Celldex Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0562-celldextherapeuticsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Celldex Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 15117B202 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t

CLDX / Celldex Therapeutics, Inc. / Polar Capital Holdings Plc Passive Investment

SC 13G 1 polar-cldx123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CELLDEX THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $.001 (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate b

CLDX / Celldex Therapeutics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15117B202 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate

CLDX / Celldex Therapeutics Inc. / Point72 Asset Management, L.P. - CELLDEX THERAPEUTICS, INC. Passive Investment

SC 13G 1 p23-2861sc13g.htm CELLDEX THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) November 10, 2023 (Date of Event Which Requires Filing of this Statement)

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

EX-99.1 2 p23-2861exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a

Calculation of Filing Fee Tables (Form Type) Celldex Therapeutics, Inc. (Exact Name of Each Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Celldex Therapeutics, Inc.

7,425,000 Shares COMMON STOCK

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-275300 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 3, 2023) 7,425,000 Shares COMMON STOCK We are offering 7,425,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “CLDX.” The last reported sale price of our common stock on November 7, 2

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Exhibit 99.1 Celldex Therapeutics Announces Proposed Public Offering of Common Stock November 7, 2023 HAMPTON, N.J., November 7, 2023 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Celldex expects to grant th

Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

Exhibit 99.2 Celldex Therapeutics Announces Pricing of Public Offering of Common Stock November 7, 2023 HAMPTON, N.J., November 7, 2023 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 7,425,000 shares of its common stock at a public offering price of $27.00 per share. In connection with the

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commis

Underwriting Agreement, dated November 7, 2023, by and among Celldex Therapeutics, Inc. and Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein

Exhibit 1.1 CELLDEX THERAPEUTICS, INC. 7,425,000 Shares of Common Stock (par value $0.001 per share)   Underwriting Agreement   November 7, 2023   JEFFERIES LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters   c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 Ladies and Gentlemen: Cell

$       COMMON STOCK

TABLE OF CONTENTS The information in this preliminary prospectus is not complete and may be changed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2023 Celldex Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commis

As filed with the Securities and Exchange Commission on November 3, 2023

As filed with the Securities and Exchange Commission on November 3, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Celldex Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exac

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Phase 2 CSU enrollment complete; topline data by YE 2023 - - Phase 1b PN data accepted at World Congress on Itch -

EXHIBIT 99.1 Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Phase 2 CSU enrollment complete; topline data by YE 2023 - - Phase 1b PN data accepted at World Congress on Itch - HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a cor

Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Phase 2 CSU enrollment completed; topline data by YE 2023 - - Phase 1b PN data in Q4 2023 - - First patient dosed in Phase 2 EoE study -

EXHIBIT 99.1 Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Phase 2 CSU enrollment completed; topline data by YE 2023 - - Phase 1b PN data in Q4 2023 - - First patient dosed in Phase 2 EoE study - HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Celldex Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commissi

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Celldex Therapeutics, Inc.

As filed with the Securities and Exchange Commission on June 21, 2023

As filed with the Securities and Exchange Commission on June 21, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Celldex Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio

Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended June 15, 2023)

Exhibit 10.1 AMENDMENT TO CELLDEX THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Dated: April 11, 2023 This Amendment amends the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”). All capitalized terms not defined herein shall have the meanings set forth in the Plan. R E C I T A L S WHEREAS, Section 17.2 of the Plan reserves to the Board of Directors (“Board”) of Ce

CLDX / Celldex Therapeutics Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15117B202 (CUSIP Number) April 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Celldex Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission

Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update - Phase 2 CSU enrollment completion expected in Q3 2023 - - Phase 1b CSU study and Phase 1 cholinergic cohort both accepted for oral presentation at EAACI 2023 - - Pha

EXHIBIT 99.1 Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update - Phase 2 CSU enrollment completion expected in Q3 2023 - - Phase 1b CSU study and Phase 1 cholinergic cohort both accepted for oral presentation at EAACI 2023 - - Phase 2 EoE study expected to initiate in June 2023 - HAMPTON, N.J., May 04, 2023 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 Celldex Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Celldex Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commi

Subsidiaries of Celldex Therapeutics, Inc.

Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. Name Jurisdiction of Organization Ownership Percentage Celldex Therapeutics Switzerland GmbH Switzerland 100%

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-15006 CELLDEX THERAPEUTICS, INC. (Exa

Description of Securities

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock summarizes the material terms and provisions of our common stock. The following description of our capital stock does not purport to be complete and is subject to, and qualified in its entirety by, our Third Restated Certifica

Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update - Phase 1b multi-dose CSU data presented at AAAAI on February 26 - - Phase 2 CSU enrollment completion expected by Q3 2023 -

EXHIBIT 99.1 Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update - Phase 1b multi-dose CSU data presented at AAAAI on February 26 - - Phase 2 CSU enrollment completion expected by Q3 2023 - HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended Decem

Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

Exhibit 99.1 Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors HAMPTON, N.J., February 16, 2023 - Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company’s Board of Directors. “We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in the Company’s trajectory,” said Anthony

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Celldex Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commi

CLDX / Celldex Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment

SC 13G/A 1 brhc10047893sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) Celldex Therapeutics, Inc. (Name of Issuer) Common stock, $.001 par value per share

CLDX / Celldex Therapeutics, Inc. / RTW INVESTMENTS, LP - CELLDEX THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p23-0592sc13ga.htm CELLDEX THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this state

CLDX / Celldex Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0540-celldextherapeuticsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Celldex Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 15117B202 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box

CLDX / Celldex Therapeutics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15117B202 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

Amended and Restated License Agreement by and between the Company and Yale University dated as of July 26, 2022

Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. EXECUTION VERSION FOURTH AMENDED AND RESTATED LICENSE AGREEMENT THIS FOURTH AMENDED AND RESTATED LICENSE AGREEMENT (this ?AGREEMENT?), dated as of June 29, 2022 (the ?FOURTH AMENDMENT EFFECTIVE DATE?), by and bet

Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Multiple clinical-stage programs on track for data updates in upcoming months -

EXHIBIT 99.1 Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Multiple clinical-stage programs on track for data updates in upcoming months - HAMPTON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. ?Celldex continued t

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Second Amended and Restated By-Laws of Celldex Therapeutics, Inc., dated November 3, 2022

? Exhibit 3.1 ? SECOND AMENDED AND RESTATED BY-LAWS OF CELLDEX THERAPEUTICS, INC. ? as of November 3, 2022 ? ARTICLE I OFFICES ? SECTION 1. REGISTERED OFFICE. The registered office of the Corporation shall be fixed in the Third Restated Certificate of Incorporation of the Corporation (as amended and/or restated from time to time, the ?Certificate of Incorporation?). ? SECTION 2. OTHER OFFICES. The

Tenth Amendment to Lease by and between the Company and University of Massachusetts Dartmouth dated as of August 1, 2022

Exhibit 10.2 TENTH AMENDMENT TO LEASE This TENTH AMENDMENT TO LEASE (this ?Amendment?) is made as of the 1st day of August, 2022, (the ?Effective Date?) by and between UNIVERSITY OF MASSACHUSETTS DARTMOUTH, an institution of Higher Education of the Commonwealth of Massachusetts, with an address of 285 Old Westport Rd. North Dartmouth Massachusetts 02747 (?Landlord?) and CELLDEX THERAPEUTICS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Third Amendment to Lease Agreement between the Company and Perryville SPE LLC (successor-in-interest) to Crown Perryville, LLC dated as of May 23, 2022

Exhibit 10.3 THIRD AMENDMENT OF LEASE THIS THIRD AMENDMENT OF LEASE, dated as of May 23, 2022, between PERRYVILLE SPE LLC (?Landlord?), and CELLDEX THERAPEUTICS, INC. (?Tenant?). W I T N E S S E T H: WHEREAS, Landlord's predecessor-in-interest, Crown Perryville, LLC., and Tenant entered into that certain Lease dated as of May 1, 2013 (the ?Original Lease?) in the building known as Perryville Ill a

Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticar

EXHIBIT 99.1 Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results fo

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2022 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio

Confidential Settlement Agreement and Mutual Release, dated July 15, 2022, by and between Shareholder Representatives Services LLC, solely in its capacity as Stockholders Representative, and Celldex Therapeutics, Inc.

Exhibit 10.1 CONFIDENTIAL SETTLEMENT AGREEMENT AND MUTUAL RELEASE This Confidential Settlement Agreement and Mutual Release (the ?Agreement?) is entered into effective as of July 15, 2022 (the ?Effective Date?) by and among Celldex Therapeutics, Inc. (?Celldex?) and Shareholder Representative Services LLC (?SRS?), in its capacity as the Stockholders representative under the Merger Agreement (defin

Binding Settlement Term Sheet, dated June 20, 2022 by and between Shareholder Representatives Services LLC, solely in its capacity as Stockholders Representative, and Celldex Therapeutics, Inc.

Exhibit 10.1 BINDING SETTLEMENT TERM SHEET This BINDING TERM SHEET (the ?Term Sheet?), is entered into as of June 20, 2022 (?Effective Date?) by and between Shareholder Representatives Services LLC (?SRS?), solely in its capacity as the Stockholders representative under the Merger Agreement (defined below), and Celldex Therapeutics, Inc. (?Celldex?). WHEREAS, on November 1, 2016, the parties enter

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2022 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2022 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio

CLDX / Celldex Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Celldex Therapeutics, Inc. (Name of Issuer) Common stock, $.001 par value per share (Title of Class of Securities) 15117B202 (CUSIP Number) May 3

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission

Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update

EXHIBIT 99.1 Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update HAMPTON, N.J., May 05, 2022 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. ?This quarter, we continued to focus on advancing our clinical programs and are on track to report data fro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

DEF 14A 1 tm223422-1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

EXHIBIT 99.1 Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update CSU Phase 1b multi-dose data expected in July CDX-0159 subcutaneous formulation study results fully support transition to SubQ dosing; Phase 2 studies in CSU and CIndU to initiate Q2 2022 Expanded development of CDX-0159 into Eosinophilic Esophagitis (EoE) Well capitalized with $408.3 mil

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commi

Subsidiaries of Celldex Therapeutics, Inc.

Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. ? ? ? ? ? ? Jurisdiction of Ownership Name ? Organization ? Percentage Celldex Therapeutics Switzerland GmbH ? Switzerland ? 100% ?

CLDX / Celldex Therapeutics, Inc. / RTW INVESTMENTS, LP - CELLDEX THERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.001 par value par value per share, of Celldex Ther

CLDX / Celldex Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Celldex therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

CLDX / Celldex Therapeutics, Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - CELLDEX THERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur

CLDX / Celldex Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Celldex Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 15117B202 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b)

Amendment No. 1 to the Amended and Restated By-Laws of Celldex Therapeutics, Inc.

Exhibit 3.1 AMENDMENT NO. 1 TO The Amended and Restated by-laws OF Celldex Therapeutics, Inc. This Amendment (this ?Amendment?) to the Amended and Restated By-Laws (the ?By-Laws?) of Celldex Therapeutics, Inc., a Delaware corporation (the ?Corporation?), has been adopted and approved by the Board of Directors of the Corporation on January 25, 2022 and is effective as of January 25, 2022. Capitaliz

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 25, 2022 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commis

CLDX / Celldex Therapeutics, Inc. / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Celldex Therapeutics Inc. (Name of Issuer) common stock (Title of Class of Securities) 15117B103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

CLDX / Celldex Therapeutics, Inc. / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Celldex Therapeutics Inc. (Name of Issuer) common stock (Title of Class of Securities) 15117B103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update HAMPTON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “During the third quarter we reported compelling data from our ongo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exac

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2021 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission F

Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Positive data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria presented at EAACI 2021 - - Raised $287 million in gross proceeds from a follow-on public

EXHIBIT 99.1 Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Positive data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria presented at EAACI 2021 - - Raised $287 million in gross proceeds from a follow-on public offering of common stock, closed in July 2021 - HAMPTON, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX)

CALCULATION OF REGISTRATION FEE

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-249917? CALCULATION OF REGISTRATION FEE ? ? Title of each class of securities to be registered ? ? ? Amount to be registered ? ? ? Proposed maximum offering price per share ? ? ? Proposed maximum aggregate offering price ? ? ? Amount of registration fee ? Common Stock, par value $0.001 per share ? ? ? 6,845,238(1) ? ? ? $42.00

-2-

Exhibit 99.2 Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) ? Celldex Therapeutics, Inc. (?Celldex? or the ?Company?) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connection with the

-2-

Exhibit 99.1 Celldex Therapeutics Announces Proposed Public Offering of Common Stock HAMPTON, N.J., July 12, 2021 (GLOBE NEWSWIRE) ? Celldex Therapeutics, Inc. (?Celldex? or the ?Company?) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $175 million of shares of its common stock in an underwritten public offering. Celldex expects to grant the un

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2021 CELLDEX THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2021 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio

Underwriting Agreement, dated July 13, 2021, by and between Celldex Therapeutics, Inc. and Jefferies LLC and SVB Leerink LLC, as representatives of the underwriters named therein

? Exhibit 1.1 ? CELLDEX THERAPEUTICS, INC. 5,952,381 Shares of Common Stock (par value $0.001 per share) ? Underwriting Agreement ? July 13, 2021 ? JEFFERIES LLC SVB LEERINK LLC As Representatives of the several Underwriters listed in Schedule A hereto ? c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 ? c/o SVB LEERINK LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 ?

SUBJECT TO COMPLETION, DATED JULY 12, 2021

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2021 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commission

Amended and Restated Employment Agreement, dated as of July 1, 2021, by and between Celldex Therapeutics, Inc. and Tibor Keler, Ph.D.

EX-10.3 4 tm2120284d1ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on July 1, 2021 (the “Effective Date”), between Tibor Keler, Ph.D. (the “Executive”) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred

Amended and Restated Employment Agreement, dated as of July 1, 2021, by and between Celldex Therapeutics, Inc. and Sarah Cavanaugh

Exhibit 10.5 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on July 1, 2021 (the ?Effective Date?), between Sarah Cavanaugh (the ?Executive?) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). W I T N E S S E T H: WHERE

Amended and Restated Employment Agreement, dated as of July 1, 2021, by and between Celldex Therapeutics, Inc. and Margo Heath-Chiozzi, M.D.

EX-10.6 7 tm2120284d1ex10-6.htm EXHIBIT 10.6 Exhibit 10.6 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of July 1, 2021 (the “Effective Date”), between Margo Heath-Chiozzi, M.D. (the “Executive”) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be

Amended and Restated Employment Agreement, dated as of July 1, 2021, by and between Celldex Therapeutics, Inc. and Ronald Pepin, Ph.D.

Exhibit 10.4 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on July 1, 2021 (the ?Effective Date?), between Ronald A. Pepin, Ph.D. (the ?Executive?) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). W I T N E S S E T H

Amended and Restated Employment Agreement, dated as of July 1, 2021, by and between Celldex Therapeutics, Inc. and Freddy Jimenez

Exhibit 10.10 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of July 1, 2021 (the ?Effective Date?), between Freddy Jimenez (the ?Executive?) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). W I T N E S S E T H: WH

Amended and Restated Employment Agreement, dated as of July 1, 2021, by and between Celldex Therapeutics, Inc. and Anthony S. Marucci

Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on July 1, 2021 (the ?Effective Date?), between Anthony S. Marucci (the ?Executive?) and CELLDEXTHERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). W I T N E S S E T H: WHE

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2021 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commission

Amended and Restated Employment Agreement, dated as of July 1, 2021, by and between Celldex Therapeutics, Inc. and Sam Martin

Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of July 1, 2021 (the ?Effective Date?), between Sam Martin (the ?Executive?) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). W I T N E S S E T H: WHEREAS

Amended and Restated Employment Agreement, dated as of July 1, 2021, by and between Celldex Therapeutics, Inc. and Diane Young, M.D.

EX-10.9 10 tm2120284d1ex10-9.htm EXHIBIT 10.9 Exhibit 10.9 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of July 1, 2021 (the “Effective Date”), between Diane Young, MD (the “Executive”) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred

Amended and Restated Employment Agreement, dated as of July 1, 2021, by and between Celldex Therapeutics, Inc. and Elizabeth Crowley

Exhibit 10.7 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on July 1, 2021 (the ?Effective Date?), between Elizabeth Crowley (the ?Executive?) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). W I T N E S S E T H: WHE

Amended and Restated Employment Agreement, dated as of July 1, 2021, by and between Celldex Therapeutics, Inc. and Richard Wright, Ph.D.

Exhibit 10.8 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on July 1, 2021 (the ?Effective Date?), between Richard Wright, Ph.D. (the ?Executive?) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the ?Company?) (collectively, the Executive and the Company shall be referred to as the ?Parties?). WHEREAS, the Executi

Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan

Exhibit 10.1 CELLDEX THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN 1. Establishment and Purpose 1.1 The purpose of the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the ?Plan?) is to provide a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietorship and personal involvement in the developmen

Celldex Therapeutics, Inc. 2021 Plan Form of Restricted Stock Award Agreement

Exhibit 10.2 RESTRICTED STOCK AWARD AGREEMENT CELLDEX THERAPEUTICS, INC. This Restricted Stock Award Agreement (the ?Agreement?), dated as of the ?Award Date? set forth in the attached Exhibit A (the ?Award Date?), is entered into between Celldex Therapeutics, Inc., a Delaware corporation (the ?Company?), and the individual named in Exhibit A hereto (the ?Awardee?). WHEREAS, the Company desires to

Celldex Therapeutics, Inc. 2021 Plan Form of Nonqualified Stock Option Grant Agreement

Exhibit 10.4 NONQUALIFIED STOCK OPTION GRANT AGREEMENT CELLDEX THERAPEUTICS, INC. This Stock Option Grant Agreement (the ?Grant Agreement?) is made and entered into effective on the Date of Grant set forth in Exhibit A (the ?Date of Grant?) by and between Celldex Therapeutics, Inc., a Delaware corporation (the ?Company?), and the individual named in Exhibit A hereto (the ?Optionee?). WHEREAS, the

Celldex Therapeutics, Inc. 2021 Plan Form of Restricted Stock Unit Award Agreement

Exhibit 10.5 RESTRICTED STOCK UNIT AWARD AGREEMENT CELLDEX THERAPEUTICS, INC. This Restricted Stock Unit Award Agreement (the ?Agreement? or ?Award Agreement?), dated as of the ?Award Date? set forth in the attached Exhibit A, is entered into between Celldex Therapeutics, Inc., a Delaware corporation (the ?Company?), and the individual named in Exhibit A hereto (the ?Awardee?). WHEREAS, the Compan

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2021 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio

Celldex Therapeutics, Inc. 2021 Plan Form of Incentive Stock Option Grant Agreement

Exhibit 10.3 INCENTIVE STOCK OPTION GRANT AGREEMENT CELLDEX THERAPEUTICS, INC. This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the “Optionee”). WHEREAS, the Com

As filed with the Securities and Exchange Commission on June 16, 2021

S-8 1 tm2119432d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on June 16, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Celldex Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3191702 (State or other jurisdiction of inco

Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update HAMPTON, N.J., May 06, 2021 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. “We are very encouraged by the recently reported positive interim result

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 6, 2021 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission File

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact name of registrant a

Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 27, 2021 (other than the portions thereof which are furnished and not filed); and

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?

Annual Report - 10-K

10-K 1 tm211037-110k.htm 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one)  ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or  ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-15006

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 29, 2021 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission F

Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results

EXHIBIT 99.1 Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2020. “Celldex made significant progress across our pipeline in 2020 and today continued this momentum with th

Subsidiaries of Celldex Therapeutics, Inc.

EX-21.1 2 tm211037d1ex21x1.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. Name Jurisdiction of Organization Ownership Percentage Celldex Therapeutics Switzerland GmbH Switzerland 100%

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Celldex Therapeutics Inc. (Name of Issuer) common stock (Title of Class of Securities) 15117B103 (CUSIP Number) February 22

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Celldex Therapeutics Inc. (Name of Issuer) common stock (Title of Class of Securities) 15117B103 (CUSIP Number) February 22, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Celldex therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) (CUSIP Number) De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Celldex therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value par value per share, of Celldex Ther

Joint Filing Statement Pursuant to Rule 13d-1(k)(1)

EX-1 2 ex1.htm Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. 1 under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of Celldex Therapeutics, Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties he

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) Dec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d

Celldex Therapeutics, Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Numbe

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 1, 2021 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commiss

Employment Agreement, dated as of January 1, 2021, by and between Freddy Jimenez and Celldex Therapeutics., Inc.

EX-10.1 2 tm2039684d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 1, 2021 (the “Effective Date”), between Freddy Jimenez (the “Executive”) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). W I T N E S S E T

Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel

EX-99.1 3 tm2039684d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel HAMPTON, N.J., January 4, 2021 - Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the promotion of Freddy A. Jimenez, Esq. to Senior Vice President and General Counsel, effective January 1, 2021. Over the span of a 30 year career in the biopharmace

Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2020 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commis

- S-3ASR

S-3ASR 1 tm2034702-1s3asr.htm S-3ASR TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 6, 2020 Registration No. 333-      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CELLDEX THERAPUETICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other j

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 5, 2020 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission

Celldex Provides Corporate Update and Reports Third Quarter 2020 Results

EXHIBIT 99.1 Celldex Provides Corporate Update and Reports Third Quarter 2020 Results HAMPTON, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2020. “In the third quarter, building on the compelling CDX-0159 data presented at EAACI, we initiated two Phase 1b studies in chronic

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact name of registra

CLDX / Celldex Therapeutics, Inc. / Logos Global Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 15117B202 (CUSIP Number) June 16, 20201 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

Other Events

8-K 1 tm2028934-18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 18, 2020 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisd

Extension of Lease Agreement between the Company and University of Massachusetts Dartmouth dated as of July 1, 2020

Exhibit 10.1 July 1, 2020 Attn: Michael LaGrassa Associate Vice Chancellor of Administrative Operations & Compliance UMass Dartmouth 285 Old Westport Road North Dartmouth, MA 02747 Dear Michael, Pursuant to Section 2.3 of the lease between UMass Dartmouth and Celldex Therapeutics (“Celldex”), as amended, (the “Lease”), Celldex is hereby providing notice of its exercise of its first two (2) year ex

Celldex Provides Corporate Update and Reports Second Quarter 2020 Results --Conference Call and Webcast today at 4:30pm ET--

EXHIBIT 99.1 Celldex Provides Corporate Update and Reports Second Quarter 2020 Results -Conference Call and Webcast today at 4:30pm ET- HAMPTON, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2020. The Company will host a conference call at 4:30 p.m. ET today to provide an update

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 f8k080620.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 6, 2020 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of

CLDX / Celldex Therapeutics, Inc. / Adage Capital Partners GP LLC - CELLDEX THERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) July 14, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant t

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated June 26, 2020 with respect to the shares of Common Stock of Celldex Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under

CLDX / Celldex Therapeutics, Inc. / Biotechnology Value Fund L P - THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number

- S-8

As filed with the Securities and Exchange Commission on June 26, 2020 Registration No.

CLDX / Celldex Therapeutics, Inc. / RTW INVESTMENTS, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Joint Filing Statement Pursuant to Rule 13d-1(k)(1)

Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of Celldex Therapeutics, Inc.

CLDX / Celldex Therapeutics, Inc. / Ikarian Capital, LLC - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Celldex Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117B202 (CUSIP Number) June 10, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat

Celldex Therapeutics, Inc. Amended and Restated 2008 Stock Option and Incentive Plan (as amended, effective June 18, 2020).

Exhibit 10.1 CELLDEX THERAPEUTICS, INC. 2008 STOCK OPTION AND INCENTIVE PLAN as amended and restated, effective as of June 15, 2017 Section 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Celldex Therapeutics, Inc. 2008 Stock Option and Incentive Plan (the "Plan"). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other k

JOINT FILING AGREEMENT June 18, 2020

EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT June 18, 2020 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (includi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2020 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio

Financial Statements and Exhibits, Other Events, Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2020 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio

Underwriting Agreement, dated June 15, 2020

EX-1.1 2 tm2022704d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 CELLDEX THERAPEUTICS, INC. 13,377,926 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement June 15, 2020 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Celldex Therapeutics, Inc., a Delawa

-2-

Exhibit 99.2 Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) – Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public offering. Celldex is offering 13,377,926 shares of its common stock, par value $0.001 per share, at a

-2-

Exhibit 99.1 Celldex Therapeutics Announces Proposed Public Offering of Common Stock HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) – Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30

13,377,926 Shares Common Stock

424B5 1 a2241895z424b5.htm 424B5 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333- 235399 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 12, 2020) 13,377,926 Shares Common Stock We are offering 13,377,926 shares of our common stock. Our common stock is traded on the Nasdaq Capital Market unde

Subject to completion, dated June 15, 2020

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

- S-3MEF

As filed with the Securities and Exchange Commission on June 15, 2020 Registration Statement No.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2020 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio

CELLDEX THERAPEUTICS, INC. Up to $18,250,000 Common Stock

424B5 1 a2241882z424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-235399 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 12, 2020) CELLDEX THERAPEUTICS, INC. Up to $18,250,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated June 12, 2020, filed as a part of our registration statement on Form S-3 (File No. 333-235399), as

-

CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 June 12, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Celldex Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3, as amended (File No. 333-235399) Ladies and Gentlemen: In accordance with Rule 461 under the Securi

Up to $75,000,000 Common Stock

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

June 12, 2020

Table of Contents As filed with the Securities and Exchange Commission on June 11, 2020 Registration Statement No.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2020 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-15006 13-3191702 (State or other jurisdiction of incorporation) (Commissio

Our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020, filed on May 6, 2020;

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact name of registrant a

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 6, 2020 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission File

Celldex Provides Corporate Update and Reports First Quarter 2020 Results

EXHIBIT 99.1 Celldex Provides Corporate Update and Reports First Quarter 2020 Results HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020. “Despite the ongoing challenges associated with the COVID-19 pandemic, Celldex continued to make considerable progress advancing our

Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 28, 2020 (other than the portions thereof which are furnished and not filed); and

DEF 14A 1 a2241464zdef14a.htm DEF 14A QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary P

CELLDEX THERAPEUTICS, INC. Up to $18,000,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-214882 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated November 9, 2017 and Prospectus dated February 13, 2017) CELLDEX THERAPEUTICS, INC. Up to $18,000,000 Common Stock This prospectus supplement amends and supplements the information in our prospectus, dated February 13, 2017, supplemented on November 9, 2017 (File No. 333-214882) (the

Ninth Amendment to Lease by and between the Company and University of Massachusetts Dartmouth dated as of October 1, 2019

Exhibit 10.13 NINTH AMENDMENT TO LEASE This NINTH AMENDMENT TO LEASE (this “Amendment”) is made as of the 1st day of October 2019, (the “Effective Date”) by and between UNIVERSITY OF MASSACHUSETTS DARTMOUTH, an institution of Higher Education of the Commonwealth of Massachusetts, with an address of 285 Old Westport Rd. North Dartmouth Massachusetts 02747 (“Landlord”) and CELLDEX THERAPEUTICS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 26, 2020 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission F

Our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 26, 2020;

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results

EXHIBIT 99.1 Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results HAMPTON, N.J., March 26, 2020 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2019. “We are pleased that Celldex entered 2020 with significant momentum, following exciting data in late 201

Description of Securities

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock summarizes the material terms and provisions of our common stock. The following description of our capital stock does not purport to be complete and is subject to, and qualified in its entirety by, our Third Restated Certifica

Subsidiaries of Celldex Therapeutics, Inc.

QuickLinks - Click here to rapidly navigate through this document Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC. Name Jurisdiction of Organization Ownership Percentage Celldex Therapeutics Switzerland GmbH Switzerland 100 % QuickLinks Exhibit 21.1 SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC.

Registration Statement on Form S-3, as amended (File No. 333-235399), initially filed with the SEC by the

S-3 1 a2240232zs-3.htm S-3 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on December 6, 2019 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CELLDEX THERAPEUTICS, INC. (Exact name of Regist

November 12, 2019

10-Q 1 a19-17579110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CE

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 12, 2019 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commissio

Celldex Provides Corporate Update and Reports Third Quarter 2019 Results

EXHIBIT 99.1 Celldex Provides Corporate Update and Reports Third Quarter 2019 Results HAMPTON, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019. “Celldex achieved a significant milestone last week, reporting data at SITC that CDX-1140 has exceeded the hurdles we defined fo

Celldex Provides Corporate Update and Reports Second Quarter 2019 Results

EXHIBIT 99.1 Celldex Provides Corporate Update and Reports Second Quarter 2019 Results HAMPTON, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2019. The Company will host a conference call at 4:30 p.m. ET today to provide an update on its pipeline and upcoming milestones for the

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 f8k080719.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 7, 2019 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of

August 7, 2019

10-Q 1 a19-10332110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 a19-1205818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 24, 2019 CELLDEX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction (

Employment Agreement, dated as of July 8, 2019, by and between Diane Young and Celldex Therapeutics., Inc.

Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of July 8, 2019 (the “Effective Date”), between Diane Young, MD (the “Executive”) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). W I T N E S S E T H: WHEREAS, as of the Effective Date the Compan

Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer

Exhibit 99.1 Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer HAMPTON, N.J., June 24, 2019 — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the appointment of Diane C. Young, M.D., as Senior Vice President, Chief Medical Officer, effective July 8, 2019. Over the span of a 30 year career, Dr. Young, a medical oncologist, has led clinical a

CLDX / Celldex Therapeutics, Inc. S-8 - - S-8

As filed with the Securities and Exchange Commission on June 21, 2019 Registration No.

CLDX / Celldex Therapeutics, Inc. S-8 - - S-8

S-8 1 a19-116201s8.htm S-8 As filed with the Securities and Exchange Commission on June 21, 2019 Registration No. 333-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3191702 (State or other jurisdiction (I.R.S. em

Celldex Therapeutics, Inc. Amended and Restated 2008 Stock Option and Incentive Plan (as amended, effective as of June 19, 2019)

Exhibit 10.1 CELLDEX THERAPEUTICS, INC. 2008 STOCK OPTION AND INCENTIVE PLAN as amended and restated, effective as of June 19, 2019 Section 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Celldex Therapeutics, Inc. 2008 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other k

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 19, 2019 CELLDEX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction (Commission File Number) (IR

Celldex Therapeutics, Inc. Amended and Restated 2004 Employee Stock Purchase Plan (effective as of June 19, 2019)

Exhibit 10.2 CELLDEX THERAPEUTICS, INC. AMENDED AND RESTATED 2004 EMPLOYEE STOCK PURCHASE PLAN (effective as of June 19, 2019) 1. Purpose. The purpose of the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Celldex Therapeutics, Inc. (the “Company”) and certain of its subsidiaries with opportunities to purchase shares of the Company’s co

CLDX / Celldex Therapeutics, Inc. DEFA14A DEFA14A

DEFA14A 1 a19-94571defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commiss

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 7, 2019 Celldex Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-15006 13-3191702 (State or Other Jurisdiction of Incorporation) (Commission File

Celldex Provides Corporate Update and Reports First Quarter 2019 Results

EXHIBIT 99.1 Celldex Provides Corporate Update and Reports First Quarter 2019 Results HAMPTON, N.J., May 07, 2019 (GLOBE NEWSWIRE) - Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2019. “Celldex presented positive data across multiple programs at AACR in April, including from our promising CDX-1140 program,” said Anth

Second Amendment to Lease Agreement between the Company and Crown Perryville, LLC dated as of March 8, 2019

Exhibit 10.1 SECOND AMENDMENT OF LEASE THIS SECOND AMENDMENT OF LEASE, dated as of March 8, 2019, between PERRYVILLE SPE LLC (“Landlord”), and CELLDEX THERAPEUTICS, INC. (“Tenant”). W I T N E S S E T H: WHEREAS, Landlord’s predecessor-in-interest, Crown Perryville, LLC., and Tenant entered into that certain Lease dated as of May 1, 2013 (the “Original Lease”), covering approximately 3,539 rentable

Our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2019, filed on May 7, 2019.

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact na